News
Video
Author(s):
Expert oncologists discuss the challenges and considerations in choosing second-line therapy for a patient with metastatic renal cell carcinoma (RCC) in a case-based context.
Biomarker-Driven Research Accelerates Drug Discovery and Precision Medicine Approaches in Sarcoma
Ponatinib-Based Regimens Strengthen the Ph+ ALL Treatment Paradigm: With Mark B. Geyer, MD, and Elias Jabbour, MD
European Commission Approves Belzutifan for VHL Disease–Associated Tumors, Advanced ccRCC
Olverembatinib Research Signals a New Era of CP-CML Management: With Elias Jabbour, MD
Tivozanib Elicits Similar PROs With or Without Nivolumab in Advanced Clear Cell RCC
Nivolumab Plus Cabozantinib Provides Durable Benefit in First-Line Advanced RCC
Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma
Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL
Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response
Piflufolastat F18 Imaging Is Associated With High Clinician Confidence in Prostate Cancer Management